Duloxetine + Placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Binge Eating
Conditions
Binge Eating, Depression
Trial Timeline
Oct 1, 2006 โ Oct 1, 2009
NCT ID
NCT00607789About Duloxetine + Placebo
Duloxetine + Placebo is a approved stage product being developed by Eli Lilly for Binge Eating. The current trial status is completed. This product is registered under clinical trial identifier NCT00607789. Target conditions include Binge Eating, Depression.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931475 | Phase 3 | Completed |
| NCT01451606 | Approved | Terminated |
| NCT01226511 | Phase 3 | Completed |
| NCT01179672 | Phase 3 | Completed |
| NCT01237587 | Phase 3 | Completed |
| NCT01118780 | Approved | Completed |
| NCT01070329 | Approved | Completed |
| NCT01000805 | Approved | Completed |
| NCT01018680 | Phase 3 | Completed |
| NCT00965081 | Approved | Completed |
| NCT00803361 | Phase 3 | Completed |
| NCT00767806 | Phase 3 | Completed |
| NCT00433290 | Phase 3 | Completed |
| NCT00424593 | Phase 3 | Completed |
| NCT00457730 | Phase 2/3 | Completed |
| NCT00408876 | Phase 3 | Completed |
| NCT00408421 | Phase 3 | Completed |
| NCT00607789 | Approved | Completed |
| NCT00375973 | Phase 2/3 | Completed |
| NCT00233025 | Phase 3 | Completed |
Competing Products
11 competing products in Binge Eating
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zonegran + sugar pill | Eisai | Phase 3 | 77 |
| Dasotraline + Placebo | Sumitomo Pharma | Phase 2/3 | 65 |
| dasotraline 4mg + dasotraline 6mg + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Dasotraline | Sumitomo Pharma | Phase 3 | 77 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol + Placebo | Jazz Pharmaceuticals | Approved | 82 |
| Sodium Oxybate | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| RDC-0313 (ALKS 33) + Placebo | Alkermes | Phase 2 | 49 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |